150 results on '"Classi, Peter"'
Search Results
2. Burden of pulmonary hypertension due to chronic obstructive pulmonary disease: Analysis of exacerbations and healthcare resource utilization in the United States
3. Considerations When Selecting Patient-Reported Outcome Measures for Assessment of Health-Related Quality of Life in Patients With Pulmonary Hypertension: A Narrative Review
4. Identifying Patients with Group 3 Pulmonary Hypertension Associated with COPD or ILD Using an Administrative Claims Database
5. INITIAL VALIDATION OF THE PULMONARY HYPERTENSION FUNCTIONAL CLASSIFICATION SELF-REPORT (PH-FC-SR): A PATIENT FOCUSED MEASURE FOR USE IN RESEARCH AND IN THE CLINIC.
6. Development of the Pulmonary Hypertension Functional Classification Self-Report: a patient version adapted from the World Health Organization Functional Classification measure
7. Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
8. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension
9. Abstract 15745: Health Outcomes in Pulmonary Arterial Hypertension Patients With COVID-19: A Real-world Analysis
10. Correction to: Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
11. Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
12. Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension
13. INITIAL TREATMENT STRATEGY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION USING TWO LARGE US ADMINISTRATIVE CLAIMS DATABASES
14. BURDEN OF ILLNESS IN PATIENTS WITH PULMONARY HYPERTENSION DUE TO COPD IN US ADMINISTRATIVE CLAIMS DATA
15. REAL-WORLD HOSPITALIZATION DIFFERENCES IN PATIENTS WITH PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE: INITIATING INHALED TREPROSTINIL VS THOSE WHO REMAIN UNTREATED
16. PATIENT-REPORTED SYMPTOM BURDEN AND HEALTH-RELATED QUALITY OF LIFE IN PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM A PATIENT'S PERSPECTIVE ON PALLIATIVE CARE ONLINE SURVEY
17. BURDEN OF ILLNESS IN PATIENTS WITH PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE: A REAL-WORLD ANALYSIS USING US CLAIMS DATA
18. HEALTHCARE RESOURCE UTILIZATION AND TREATMENT PATTERNS BEFORE AND AFTER INITIATION OF INHALED TREPROSTINIL
19. HEALTH OUTCOMES AND COSTS ASSOCIATED WITH ORAL TREPROSTINIL AND SELEXIPAG ONE YEAR INTO TREATMENT: A UNITED STATES CLAIMS DATABASE ANALYSIS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
20. EXPRESS: Reasons for Refusing Parenteral Therapy: A Qualitative Study of Patients with Pulmonary Arterial Hypertension
21. sj-pdf-1-pul-10.1177_20458940211046761 - Supplemental material for Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
22. sj-pdf-1-pul-10.1177_20458940211005641 - Supplemental material for Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life
23. CLINICAL RELEVANCE OF FATIGUE AS A RESIDUAL SYMPTOM IN MAJOR DEPRESSIVE DISORDER
24. Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life
25. DEVELOPMENT OF THE PULMONARY HYPERTENSION FUNCTIONAL CLASSIFICATION SELF-REPORT (PH-FC-SR)
26. REASONS FOR REFUSING PARENTERAL THERAPY: A QUALITATIVE STUDY OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
27. LOW UTILIZATION OF PROSTACYCLIN THERAPY PRIOR TO DEATH AMONG MEDICARE PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
28. CONTEMPORARY DOSING CHARACTERISTICS OF ORAL TREPROSTINIL IN REAL-WORLD CLINICAL PRACTICE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
29. Antibiotic Treatment Failure and Associated Outcomes Among Adult Patients With Community-Acquired Pneumonia in the Outpatient Setting: A Real-world US Insurance Claims Database Study
30. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension
31. Social and emotional difficulties in children with ADHD and the impact on school attendance and healthcare utilization
32. Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review
33. Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms
34. Patient characteristics, comorbidities, and medication use for children with ADHD with and without a co-occurring reading disorder: A retrospective cohort study
35. Economic burden and comorbidities of attention-deficit/hyperactivity disorder among pediatric patients hospitalized in the United States
36. Preferences related to attention-deficit/hyperactivity disorder and its treatment
37. What happens next?: A Claims Database Study of Second-Line Pharmacotherapy in Patients with Major Depressive Disorder (MDD) Who Initiate Selective Serotonin Reuptake Inhibitor (SSRI) Treatment.
38. What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment
39. Preferences related to attention-deficit/hyperactivity disorder and its treatment
40. CLINICAL RELEVANCE OF FATIGUE AS A RESIDUAL SYMPTOM IN MAJOR DEPRESSIVE DISORDER
41. Adjunctive pharmacotherapy and treatment patterns among initiators of SSRI therapy for major depressive disorder: A cohort study using a primary care database
42. Discontinuation of antidepressant therapy among patients with major depressive disorder
43. Patient Preferences for Treatment of Major Depressive Disorder and the Impact on Health Outcomes
44. The Co-occurrence of Reading Disorder and ADHD
45. Economic burden and comorbidities of attention-deficit/hyperactivity disorder among pediatric patients hospitalized in the United States
46. Utilization of a Sport-Specific Instrument to Predict Clutch Performance
47. Validation of a Sport Specific Coping Skills Inventory for Athletes
48. The Co-occurrence of Reading Disorder and ADHD: Epidemiology, Treatment, Psychosocial Impact, and Economic Burden.
49. What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment.
50. Preferences related to attention-deficit/hyperactivity disorder and its treatment.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.